Here's Why the Best Is Yet to Come for Novavax, Inc.

Here's Why the Best Is Yet to Come for Novavax, Inc.

Synthetic vaccine maker Novavax (NASDAQ: NVAX) has fallen on hard times. The dramatic failure of its closely watched respiratory syncytial virus fusion (RSV F) vaccine in elderly adults last year has caused investors to reconsider whether its platform is even viable. 

Novavax's stock has lost over 90% of its value in the past year, and its shares are currently bumping up against the Nasdaq's $1 minimum bid requirement. Put simply, this clinical-stage biotech is essentially on life support at this stage. 

Image source: Getty Images.

Continue reading

Source: Fool.com